RxDoctor Payments Data

Shreya Ghetiya, MD

Cardiovascular Disease · Jacksonville, FLNPI 1508253600

Payments from drug & device makers

$22,945in general payments, 2019–2025

Across 393 payments — averaging $58.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$9K
  • Abbott$3K
  • Edwards Lifesciences$3K
  • Siemens Medical Solutions USA, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$842
  • plus $5K from 27 others

What the payments were for

  • Speaking & faculty fees$8,27036%
  • Travel & lodging$4,90221%
  • Food & beverage$9,54842%
  • Education$2251%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,945 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$214,107
Medicare patients
1,237
Services billed
3,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$264,229
CamzyosMavacamten32$261,652
VyndamaxTafamidis11$245,655
EntrestoSacubitril/Valsartan131$151,740
JardianceEmpagliflozin134$132,405
FarxigaDapagliflozin Propanediol97$108,029
Repatha SureclickEvolocumab156$106,210
XareltoRivaroxaban77$85,152
VascepaIcosapent Ethyl32$18,056
Praluent PenAlirocumab32$15,838
Metoprolol Succinate445$5,886
Rosuvastatin Calcium382$5,073
Atorvastatin Calcium410$4,548
Carvedilol369$4,037
Ranolazine ErRanolazine26$2,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$509$509,884251 claims
E.r. Squibb & Sons, L.L.C.Camzyos$1,015$261,65232 claims
NovartisEntresto$842$151,740131 claims
Boehringer IngelheimJardiance$8,624$132,405134 claims
AstraZenecaFarxiga$339$108,02997 claims
Johnson & JohnsonXarelto$207$85,15277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →